Eli Lilly Claims that a single infusion of an Experimental Drug can Reduce the Risks of Coronavirus


Drugmaker Eli Lilly claimed that an experimental drug could reduce the risks of coronavirus. The drug is a monoclonal antibody, a manufactured copy of an antibody produced by a patient who recovered from Covid-19.

Many scientists hope that this drug will prove to be a treatment for Covid-19, but the drug is hard to manufacture and expensive. Moreover, Eli Lilly did not disclose much details about the drug.

Around 450 newly diagnosed patients were infused with the monoclonal antibody. There was a 72% reduction in the risk of the disease, and only 1.7 of the patients were hospitalized.

These results gave been received with great rigor by health experts. Dr. Myron Cohen, director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, said that the results of the drug were compelling. More research should be done to develop it.

Rajesh T. Gandhi, an infectious disease specialist at Massachusetts General Hospital, is also impressed with Eli Lilly and its research. He applauded the drugmaker for studying people with mild to moderate disease. As 80% of the patients have mild to moderate disease, we need a drug that would cater to their needs

The monoclonal antibody is manufactured by using the plasma of recovered COVID-19 patients. However, the process is expensive, which makes the drug hard to manufacture. T. Gandhi said he would like to see more data on the study of monoclonal antibodies. Eli Lilly has opened a door for a COVID-19 drug that would actually work.


Sherlyn has been persistent in her aim to revolutionize the field of medical journalism. She brings years of journalism as well as her clinical expertise as a retired M.D. from a reputed health care centre. She is passionate about everything that is latest in the health sector.

Leave a Reply

Your email address will not be published. Required fields are marked *